Bio Protocol, the decentralized science (DeSci) platform building AI-native infrastructure for biotechnology, announced it has raised $6.9 million in a funding round anchored by Maelstrom Fund, with participation from leading biotech and crypto investors. The financing fuels Bio Protocol's expansion into a full-stack platform for AI-driven decentralized science, scientific funding and drug discovery.

A Platform for AI-Driven Decentralized Science

Bio Protocol enables distributed groups of researchers, patients and crypto users to create and grow AI-driven research networks that automate scientific tasks and monetize biotech discoveries.

While AI in biology is rapidly advancing through initiatives at Google, OpenAI, and Stanford, most scientific AI tools remain siloed in traditional pharma and cut off from global collaboration. Bio integrates scientific AI with blockchain features for coordination, funding and data integrity, allowing biotech research to move faster from hypothesis to commercial application.

Paul Kohlhaas, founder and CEO of Bio Protocol: "Science today is locked in institutional black boxes, cut off from the very researchers who birth it and the communities primed to accelerate it. By unifying AI, biotech, and crypto in a decentralized platform, researchers and citizen scientists everywhere can collaborate more efficiently and back promising biotech from its earliest stages, compressing drug development from decades to months."

Arthur Hayes, founder and CIO of Maelstrom Fund: "Bio is about to be the category-defining launchpad which will fund scientific research the community finds appealing, not just academics. If it works, it's not just a launchpad - it's the birth of an AI-native research market."